NFKB1 overexpression
|
Melanoma
|
NFKB1 overexpression
|
Melanoma
|
PD1 inhibitor Resistant: C3 – Early Trials
|
PD1 inhibitor Resistant: C3 – Early Trials
|
NFKB1 overexpression
|
AML
|
NFKB1 overexpression
|
AML
|
cytarabine + doxorubicin hydrochloride Resistant: C3 – Early Trials
|
cytarabine + doxorubicin hydrochloride Resistant: C3 – Early Trials
|
NFKB1 overexpression
|
Pancreatic Cancer
|
NFKB1 overexpression
|
Pancreatic Cancer
|
albumin-bound paclitaxel Resistant: D – Preclinical
|
albumin-bound paclitaxel Resistant: D – Preclinical
|